Atlantic Grupa (ATGR) Q4 2025 earnings summary

Executive summary

• Achieved strong revenue growth and improved profitability in FY 2025, with sales reaching EUR 1.19 billion, up 10.2% year-over-year, and normalized EBITDA of EUR 103.4 million, up 13.8%.

• Launched two new brands (Lemonish and DoNatural), completed the sale of Montana Plus, acquired Deltis Pharm pharmacies, and relocated coffee production to Šimanovci.

• Issued new bonds at a fixed 2.875% rate and paid a dividend of EUR 1.50 per share.

• Received numerous awards and recognitions, and underwent changes in the Management and Supervisory Boards.

Financial highlights

• Sales revenue grew 10.2% to EUR 1,190.0 million compared to 2024.

• Normalized EBITDA increased 13.8% to EUR 103.4 million; normalized EBIT rose 26.0% to EUR 50.0 million.

• Net profit grew 20.9% year-over-year to EUR 32.1 million.

• Free cash flow declined to EUR 1.3 million from EUR 18.5 million in 2024.

• Capital expenditure reached EUR 52.1 million, a record level.

Outlook and guidance

• 2025 results were in line with outlook; 2026 guidance expects sales above EUR 1.25 billion and normalized EBITDA above EUR 110 million.

• CAPEX for 2026 is projected to exceed EUR 60 million.